Want to see SION full AI Analyst Report?
Total Valuation
Sionna Therapeutics, Inc. has a market cap or net worth of $1.99B. The enterprise value is $1.60B.
Market Cap$1.99B
Enterprise Value$1.60B
Share Statistics
Sionna Therapeutics, Inc. has 45,150,330 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding45,150,330
Owned by Insiders34.50%
Owned by Institutions13.30%
Financial Efficiency
Sionna Therapeutics, Inc.’s return on equity (ROE) is -0.25 and return on invested capital (ROIC) is -28.20%.
Return on Equity (ROE)-0.25
Return on Assets (ROA)-0.23
Return on Invested Capital (ROIC)-28.20%
Return on Capital Employed (ROCE)-0.28
Revenue Per Employee0.00
Profits Per Employee-1.84M
Employee Count41
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Sionna Therapeutics, Inc. is ―. Sionna Therapeutics, Inc.’s PEG ratio is -0.64.
PE Ratio―
PS Ratio0.00
PB Ratio5.36
Price to Fair Value5.36
Price to FCF-24.66
Price to Operating Cash Flow-27.50
PEG Ratio-0.64
Income Statement
In the last 12 months, Sionna Therapeutics, Inc. had revenue of 0.00 and earned -75.27M in profits. Earnings per share was -1.88.
Revenue0.00
Gross Profit-647.00K
Operating Income-88.98M
Pretax Income-75.27M
Net Income-75.27M
EBITDA-74.62M
Earnings Per Share (EPS)-1.88
Cash Flow
In the last 12 months, operating cash flow was -71.85M and capital expenditures -291.00K, giving a free cash flow of -72.14M billion.
Operating Cash Flow-71.85M
Free Cash Flow-72.14M
Free Cash Flow per Share-1.60
Dividends & Yields
Sionna Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.18
52-Week Price Change109.88%
50-Day Moving Average32.75
200-Day Moving Average―
Relative Strength Index (RSI)71.28
Average Volume (3m)397.51K
Important Dates
Sionna Therapeutics, Inc. upcoming earnings date is Aug 17, 2026, Before Open (Confirmed).
Last Earnings DateMay 12, 2026
Next Earnings DateAug 17, 2026
Ex-Dividend Date―
Financial Position
Sionna Therapeutics, Inc. as a current ratio of 20.61, with Debt / Equity ratio of 2.91%
Current Ratio20.61
Quick Ratio20.61
Debt to Market Cap0.00
Net Debt to EBITDA0.67
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Sionna Therapeutics, Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Sionna Therapeutics, Inc. EV to EBITDA ratio is -21.36, with an EV/FCF ratio of -23.91.
EV to Sales0.00
EV to EBITDA-21.36
EV to Free Cash Flow-23.91
EV to Operating Cash Flow-24.05
Balance Sheet
Sionna Therapeutics, Inc. has $216.15M in cash and marketable securities with $8.38M in debt, giving a net cash position of $207.77M billion.
Cash & Marketable Securities$216.15M
Total Debt$8.38M
Net Cash$207.77M
Net Cash Per Share$4.60
Tangible Book Value Per Share$7.68
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Sionna Therapeutics, Inc. is $51.71, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$51.71
Price Target Upside18.77% Upside
Analyst ConsensusModerate Buy
Analyst Count9
Revenue Growth Forecast―
EPS Growth Forecast-27.48%